United Capital Financial Advisers, LLC Amarin Corp Plcuk Transaction History

United Capital Financial Advisers, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.09 - $1.67 $637 - $976	-585 Reduced 5.16%	10,759 $12,000
Q2 2022 Aug 11, 2022	SELL	$1.13 - $3.69 $446 - $1,457	-395 Reduced 3.36%	11,344 $17,000
Q1 2022 May 16, 2022	SELL	$2.85 - $3.73 $25,023 - $32,749	-8,780 Reduced 42.79%	11,739 $39,000
Q4 2021 Feb 14, 2022	BUY	$3.24 - $5.18 $15,552 - $24,864	4,800 Added 30.54%	20,519 $69,000
Q3 2021 Nov 15, 2021	BUY	$3.94 - $5.84 $788 - $1,168	200 Added 1.29%	15,719 $80,000
Q1 2021 May 14, 2021	BUY	$5.03 - $8.8 $78,060 - $136,567	15,519 New	15,519 $96,000
Q4 2020 Feb 17, 2021	SELL	$4.04 - $5.31 $54,952 - $72,226	-13,602 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$4.0 - $21.53 $1,148 - $6,179	287 Added 2.16%	13,602 $54,000
Q4 2019 Feb 14, 2020	BUY	$13.94 - $24.12 $17,661 - $30,560	1,267 Added 10.52%	13,315 $285,000
Q3 2019 Nov 14, 2019	BUY	$13.89 - $23.16 $875 - $1,459	63 Added 0.53%	12,048 $183,000
Q1 2019 May 14, 2019	BUY	$12.61 - $22.33 $14,501 - $25,679	1,150 Added 10.61%	11,985 $249,000
Q4 2018 Feb 14, 2019	BUY	$12.41 - $22.98 $134,462 - $248,988	10,835 New	10,835 $147,000

177

65.1M

258K

98K

Ticker AMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 403,206,016
Market Cap $177M
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...

Get notified when there are updates to the investment portfolio of United Capital Financial Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on United Capital Financial Advisers, LLC with notifications on news.